M.D.
Hematologist
2000, M.B.B.S., Aga Khan University Medical College, Karachi, Pakistan
2009-2010, Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2006-2009, Hmatology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
2003-2006, Internal Medicine, University of Connecticut Health Center, Farmington, Connecticut
2022-present, Medical Director of Lymphoma, City of Hope, Orange County, CA
2019-present, Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center, City of Hope, Duarte, California
2024-present, Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2018-2024, Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
Tanya Siddiqi, M.D., is a highly respected hematologist-oncologist who focuses on treating blood cancers, with a particular expertise in chronic lymphocytic leukemia and B cell non-Hodgkin lymphoma. Dr. Siddiqi is also the director of the Chronic Lymphocytic Leukemia Program at the Toni Stephenson Lymphoma Center at City of Hope® Cancer Center Duarte.
In addition to her clinical work, Dr. Siddiqi leads clinical research aimed at advancing treatment options for hematologic malignancies, including exploring leading-edge therapies like targeted treatments and CAR T cell therapy.
Dr. Siddiqi received her medical degree from Aga Khan University Medical College in Karachi, Pakistan. She completed her residency in internal medicine at the University of Connecticut Health Center in Farmington, followed by advanced training in hematology and oncology at Beth Israel Deaconess Medical Center in Boston. She pursued a further specialization in stem cell transplantation at City of Hope.
Dr. Siddiqi is an integral member of City of Hope’s Toni Stephenson Lymphoma Center, the Immunotherapy Disease Team, and the Gehr Family Center for Leukemia Research, where she continues to push the boundaries of what's possible in blood cancer treatment.